265 Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease and Toxicity
Last Updated: Monday, December 12, 2022
Orca-T, a high-precision, immunotherapy consisting of stem and immune cells, reduced GVHD rates in a phase 2 trial of 180 leukemia patients. A phase 3 trial comparing Orca-T to standard of care is currently enrolling patients.
Advertisement
News & Literature Highlights